Search - tctmd.com

Displaying 21 - 37 of 37

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Daily News

Edwards Voluntarily Recalls Cardioband ‘Anchors’ Used in Mitral and Tricuspid Repair

Michael O'Riordan

February 27, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

Caitlin E. Cox

September 08, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Daily News

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

L.A. McKeown

December 13, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2018

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

TCTMD’s Top 10 Most Popular Stories for August 2018

Edwards Voluntarily Recalls Cardioband ‘Anchors’ Used in Mitral and Tricuspid Repair

TCTMD’s Top 10 Most Popular Stories for October 2017

TCTMD’s Top 10 Most Popular Stories for September 2017

No More Absorb BVS: Abbott Puts a Stop to Sales

TCTMD’s Top 10 Most Popular Stories for May 2017

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Absorb BVS Recalled in Australia From All Centers Not Studying Device

TCTMD’s Top 10 Most Popular Stories for April 2017

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content